Zoetis shares have fallen 36.6% over the past six months to $78.46 per share, partly due to softer quarterly results. The company’s constant currency revenue grew at an average annual rate of 8.7% over the last two years, indicating steady global demand. Its five-year average return on invested capital stands at 28.6%, placing it among the most efficient healthcare companies. However, annualized revenue growth over the past five years was a more modest 6.1%, which lags some peers in the sector. The stock now trades at 11.2 times forward earnings.
Zoetis IncStock dropped 36.6% due to softer quarterly results and trades at 11.2x forward earnings
Pfizer Inc